These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9819884)

  • 1. [Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke].
    Gekht AB; Burd GS; Selikhova MV; Iaish F; Beliakov VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(10):22-9. PubMed ID: 9819884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The use of sirdalud in painful muscle tonic syndromes].
    Damulin IV
    Ter Arkh; 1997; 69(10):68-72. PubMed ID: 9471796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
    Lipták J
    Ideggyogy Sz; 2013 Nov; 66(11-12):429. PubMed ID: 24555245
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tizanidine as treatment of spasticity in patients with hemiplegia caused by a CVA or brain injury].
    Weynants L; Van Laere M
    Acta Belg Med Phys; 1990; 13(1):19-22. PubMed ID: 2336897
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-spasticity medications.
    Al-Shahrani AM
    Saudi Med J; 2003 Jan; 24(1):19-22. PubMed ID: 12590267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of gait and isokinetic movements for evaluation of antispastic drugs or physical therapies.
    Knutsson E
    Adv Neurol; 1983; 39():1013-34. PubMed ID: 6229155
    [No Abstract]   [Full Text] [Related]  

  • 8. [The use of sirdalud MR in patients with multiple sclerosis].
    Batysheva TT; Popova NF; Petrov SV; Kamchatnov PR; Zaĭtsev KA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):57-60. PubMed ID: 21322181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
    Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
    Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The treatment of tension headache with sirdalud].
    Filatova EG; Solov'eva AD; Danilov AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(11):36-8. PubMed ID: 9463035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexor reflex for assessment of common interneurone activity in spasticity.
    Milanov IG
    Electromyogr Clin Neurophysiol; 1992 Dec; 32(12):621-9. PubMed ID: 1493777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy of sirdalud in the drug therapy of pain in the spine].
    Iakhno NN; Damulin IV; Chernenko OA; Ianakaeva TA; Kondrat'eva ON; Kur'ianova PT
    Ter Arkh; 1994; 66(10):10-2. PubMed ID: 7863433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).
    Emre M; Leslie GC; Muir C; Part NJ; Pokorny R; Roberts RC
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57(11):1355-9. PubMed ID: 7964811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease.
    Ogawa N; Asanuma M; Hirata H; Ota Z; Yamawaki Y; Yamamoto M
    J Int Med Res; 1992 Feb; 20(1):78-86. PubMed ID: 1568522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population.
    Smith HS; Barton AE
    Am J Hosp Palliat Care; 2000; 17(1):50-8. PubMed ID: 11094920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic management of spasticity following stroke.
    Gallichio JE
    Phys Ther; 2004 Oct; 84(10):973-81. PubMed ID: 15449979
    [No Abstract]   [Full Text] [Related]  

  • 18. The pharmacological management of spasticity.
    Saulino M; Jacobs BW
    J Neurosci Nurs; 2006 Dec; 38(6):456-9. PubMed ID: 17233517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.
    Mathias CJ; Luckitt J; Desai P; Baker H; el Masri W; Frankel HL
    J Rehabil Res Dev; 1989; 26(4):9-16. PubMed ID: 2600869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
    Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
    Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.